Updated on 14 September 2026
Patent-Pending Nanotechnology Platform for Immune Cell–Tumor Cell Engagement
Profesor Titular Universidad at Grupo de Nanotecnologia Orgánica - UPM
Madrid, Spain
About
We have developed a proprietary, patent-pending nanotechnology platform designed to improve cancer immunotherapy by selectively connecting immune cells with tumor cells.
The platform promotes immune cell–tumor interaction and redirects immune responses toward cancer cells without requiring complex genetic modification of immune cells.
We are seeking clinical and industrial partners with complementary expertise in cancer immunotherapy, cell therapy, preclinical models and translational research. Potential collaborations include joint validation studies, co-development of new therapeutic applications and participation in national and international collaborative R&D projects.
Our goal is to establish strategic partnerships to accelerate preclinical development and explore the application of this technology across different tumor types and immunotherapeutic strategies.
Looking for
- Development
Organisation
Similar opportunities
Investment
Patent-Pending Nanotechnological Platform to Redirect Immune Cells Against Cancer
- Startup
- Healthcare
- Nano- and Microtechnologies
- Biotech, Pharma and Cosmetics
Alejandro Baeza García
Profesor Titular Universidad at Grupo de Nanotecnologia Orgánica - UPM
Madrid, Spain
Product
GMP Recombinant Cytokines & Growth Factors for Cell & Gene Therapy Manufacturing
- Importer
- Health innovation
- Distribution Partner
- Laboratory industry
- Pharmaceutical industry
俊翰 趙
Business Development manager at Croyez Bioscience
Taipei, Taiwan
Product
Ana Somé
Technology Transfer Manager - Specialist on Intellectual Property at OTRI-Universidad de Malaga
Málaga, Spain